JP2017214420A5 - - Google Patents

Download PDF

Info

Publication number
JP2017214420A5
JP2017214420A5 JP2017159116A JP2017159116A JP2017214420A5 JP 2017214420 A5 JP2017214420 A5 JP 2017214420A5 JP 2017159116 A JP2017159116 A JP 2017159116A JP 2017159116 A JP2017159116 A JP 2017159116A JP 2017214420 A5 JP2017214420 A5 JP 2017214420A5
Authority
JP
Japan
Prior art keywords
tumor
composition
dash inhibitor
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017159116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017214420A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017214420A publication Critical patent/JP2017214420A/ja
Publication of JP2017214420A5 publication Critical patent/JP2017214420A5/ja
Pending legal-status Critical Current

Links

JP2017159116A 2011-11-22 2017-08-22 樹状細胞癌ワクチンのための小分子エンハンサー Pending JP2017214420A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161562497P 2011-11-22 2011-11-22
US61/562,497 2011-11-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014543501A Division JP6240083B2 (ja) 2011-11-22 2012-11-15 樹状細胞癌ワクチンのための小分子エンハンサー

Publications (2)

Publication Number Publication Date
JP2017214420A JP2017214420A (ja) 2017-12-07
JP2017214420A5 true JP2017214420A5 (cg-RX-API-DMAC7.html) 2018-02-08

Family

ID=48470210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543501A Active JP6240083B2 (ja) 2011-11-22 2012-11-15 樹状細胞癌ワクチンのための小分子エンハンサー
JP2017159116A Pending JP2017214420A (ja) 2011-11-22 2017-08-22 樹状細胞癌ワクチンのための小分子エンハンサー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014543501A Active JP6240083B2 (ja) 2011-11-22 2012-11-15 樹状細胞癌ワクチンのための小分子エンハンサー

Country Status (9)

Country Link
US (3) US9284337B2 (cg-RX-API-DMAC7.html)
EP (2) EP2782994B1 (cg-RX-API-DMAC7.html)
JP (2) JP6240083B2 (cg-RX-API-DMAC7.html)
CN (2) CN106075450A (cg-RX-API-DMAC7.html)
AU (2) AU2012340887A1 (cg-RX-API-DMAC7.html)
CA (1) CA2856379A1 (cg-RX-API-DMAC7.html)
HK (1) HK1201871A1 (cg-RX-API-DMAC7.html)
IL (1) IL232664A0 (cg-RX-API-DMAC7.html)
WO (1) WO2013078059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284337B2 (en) * 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
WO2016085943A1 (en) 2014-11-25 2016-06-02 Rastelli, Luca Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11000521B2 (en) 2015-08-03 2021-05-11 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
WO2018049027A1 (en) * 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
WO2018187698A2 (en) * 2017-04-07 2018-10-11 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040145A (en) * 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
CA2339537A1 (en) * 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity
HK1046846A1 (zh) 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN100392074C (zh) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
CN101247799B (zh) * 2005-07-05 2013-03-27 塔夫茨大学信托人 成纤维细胞活化蛋白α的抑制剂
CN101379069A (zh) * 2005-12-19 2009-03-04 塔夫茨大学信托人 软蛋白酶抑制剂及其前软形式
WO2007123686A2 (en) * 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof
CA2681351A1 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP2154243B1 (en) * 2007-05-17 2016-01-13 ID Pharma Co., Ltd. Method for production of dendritic cell
JP5721441B2 (ja) * 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーCurevac Gmbh 免疫賦活剤/アジュバントとしての式(I)(NuGlXmGnNv)aで表される核酸分子及びその誘導体
US9284337B2 (en) * 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines

Similar Documents

Publication Publication Date Title
JP2014533727A5 (cg-RX-API-DMAC7.html)
ES2539603T3 (es) Agente inductor de inmunidad
KR102566924B1 (ko) 케모카인 수용체 조절제 및 이의 용도
US9776978B2 (en) 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
US9839646B2 (en) Small molecule enhancer for dendritic cell cancer vaccines
JP2017536344A5 (cg-RX-API-DMAC7.html)
JP2017519753A5 (cg-RX-API-DMAC7.html)
JP2018507197A5 (cg-RX-API-DMAC7.html)
JP2019512478A5 (cg-RX-API-DMAC7.html)
JP2016534059A5 (cg-RX-API-DMAC7.html)
JP2018504379A5 (cg-RX-API-DMAC7.html)
JP2016514103A5 (ja) 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
JP2016519062A5 (cg-RX-API-DMAC7.html)
CN111918652A (zh) 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂
JP5201995B2 (ja) ジアザベンゾ[デ]アントラセン−3−オン化合物、及び、parpの阻害方法
CN1516600A (zh) 用于治疗肿瘤疾病的联合药物
JP2014532751A5 (cg-RX-API-DMAC7.html)
JP2008506710A5 (cg-RX-API-DMAC7.html)
JP2005508857A5 (cg-RX-API-DMAC7.html)
KR102275112B1 (ko) 5-브로모-인디루빈
TWI796326B (zh) 含有axl抑制劑與egfr酪胺酸激酶抑制藥的醫藥品及其用途
JP2017509672A5 (cg-RX-API-DMAC7.html)
JP2009527463A5 (cg-RX-API-DMAC7.html)
JP2023514426A5 (cg-RX-API-DMAC7.html)
CN119241434A (zh) 固有免疫激活药物及其用途